halofuginone has been researched along with Skin Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J; Lv, T; Wang, H; Wang, X; Wu, M; Zeng, Q | 1 |
| Geffrotin, C; Gerritsen, MJ; Mamor-Cornelissen, I; Rijntjes, J; Ruiter, DJ; van Dijk, MC; van Kempen, LC; van Muijen, GN; Vincent-Naulleau, S | 1 |
2 other study(ies) available for halofuginone and Skin Neoplasms
| Article | Year |
|---|---|
Halofuginone enhances the anti-tumor effect of ALA-PDT by suppressing NRF2 signaling in cSCC.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Mice; NF-E2-Related Factor 2; Photochemotherapy; Photosensitizing Agents; Piperidines; Quinazolinones; Skin Neoplasms | 2022 |
Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma.
Topics: Angiogenesis Inhibitors; Animals; Collagen Type I; Humans; Immunohistochemistry; In Situ Hybridization; Melanoma; Neoplasm Invasiveness; Neovascularization, Pathologic; Piperidines; Quinazolinones; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Swine; Swine, Miniature | 2008 |